L’Oréal and Galderma’s 2026 data shows that growth in prestige beauty is driven not by formulas or luxury marketing, but by licensed intermediaries like dermatologists, prescribers, and salon professionals. While luxury skincare recovers slowly, prescription and professional categories are surging—a trend amplified by GLP-1 treatments and supply chain strength in Korean pharma and manufacturers.
